
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 5, 2026, 4:05 PM ET
Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates
Nasdaq: $SANABiotech · engineered cell therapiesHypoimmune platformCash runway into mid-2027Two clinical starts in the next two quarters
SANA Stock Hub: Sana Biotechnology News, SC451 and SG293
Sana is trying to solve the two problems that keep cell therapy expensive: the immune system rejects cells that are not the patient’s own, and engineering T cells inside a patient has required a manufacturing plant. Its hypoimmune platform edits donor cells so they escape rejection without immunosuppression, and a first patient has now carried engineered islet cells for 14 months with measurable C-peptide and no immunosuppression. The company had $121.7 million of cash at September 30, 2026, a runway into mid-2027, and two clinical starts planned: SC451 in type 1 diabetes and SG293 in lymphoma.
Full research report · PDF
Sana Biotechnology, Inc. ($SANA) research report, updated November 19, 2026
15 pages: the hypoimmune platform and the UP421 first-in-human data, SC451 and the type 1 diabetes opportunity, SG293 and in vivo CAR T, SG227, the third-quarter 2026 accounts, cash and burn, the share count and the 2026 financings, the 2025 restructuring, scenarios, sources and FAQ. Available in the Merlintrader Research Library. The report is a dated snapshot and is not updated after that date; this page follows the current situation. For personal use only: redistribution prohibited.
Next catalyst
As early as 2026 · investigational new drug application and start of the SC451 Phase 1/2 trial in type 1 diabetes
Sana says it expects to file the investigational new drug application and begin a Phase 1/2 trial for SC451, an O-negative, hypoimmune-modified, induced pluripotent stem cell (iPSC)-derived islet cell therapy, as early as this year. The company also expects to start a clinical study of SG293, a CD8-targeted fusosome that generates CD19-directed CAR T cells in vivo, in the first quarter of 2027, with first-in-human data in non-Hodgkin lymphoma as early as the first half of 2027. Third-quarter release, November 5, 2026
Completed: on November 5, 2026 Sana reported third-quarter results, a GAAP net income of $20.4 million driven by non-cash gains on contingent consideration, and $121.7 million of cash and marketable securities (release). In 2026 the New England Journal of Medicine published a letter on the 14-month UP421 results (chapter 03). In August 2026 Sana amended the Cobalt acquisition agreement, which reduced the estimated contingent consideration, deferred certain milestone payments until a change of control of Sana and produced a $55.5 million non-cash gain in the quarter.
SANA stock at a glance
Chart analysis · JC
Technical chart analysis of $SANA with bull and bear scenarios on JC Just Charts.
Cash + securities · Sep 30
$121.7M
From $138.4M at December 31, 2025; the company guides to a runway into mid-2027.
Revenue
$0
No revenue from product sales or any other source since inception; the company is pre-commercial.
Net income · third quarter
$20.4M
$0.07 per share, driven by $63.4M of non-cash gains on success payment liabilities and contingent consideration; nine-month net loss $90.4M.
R&D · third quarter
$33.9M
Against $30.1M a year earlier, on manufacturing for SC451 and SG293; nine months $93.4M against $97.1M.
Operating cash burn · 9M
$103.4M
Non-GAAP, against $108.0M in the same period of 2025; cash used in operations on a GAAP basis was $108.9M.
Shares · Sep 30
299.5M
299,521 thousand shares, from 266,732 thousand at December 31, 2025, after $93.3M of net equity proceeds.
Where Sana stands now
Sana Biotechnology is a Seattle company built on two ideas about delivering cells and genes. The first is hypoimmune editing: deleting the genes that present donor tissue to the immune system and overexpressing CD47 so that macrophages do not eat the cells, which in principle lets an allogeneic transplant survive without immunosuppression. The second is fusosomes, engineered envelopes that deliver genetic material to a chosen cell type inside the body, which in principle lets a patient make their own chimeric antigen receptor (CAR) T cells without a manufacturing plant.
Both ideas have moved from mice to humans in the past two years. UP421, a primary islet cell product edited with the hypoimmune modifications, was transplanted into a patient with type 1 diabetes at Uppsala University Hospital without any immunosuppression, and the company reported 14 months of circulating C-peptide and no safety issues in 2026, a result also published as a letter in the New England Journal of Medicine (details in chapter 03). Third-quarter release, November 5, 2026
The risk that matters. Sana had $121.7 million of cash and marketable securities at September 30, 2026 and guides to a runway into mid-2027, while its non-GAAP cash burn was $103.4 million in the first nine months of 2026, about $138 million at that annual pace (Merlintrader calculation). The Form 10-Q for the quarter states that current capital resources may not be sufficient to fund planned operations for at least one year and that there is substantial doubt about the company’s ability to continue as a going concern. Two clinical programs are supposed to start in the next two quarters, and both will consume cash before they produce data. Sana sold 7.5 million shares to Mayo Clinic in April 2026 and has an at-the-market facility of up to $150.0 million; it will need to raise again before the runway ends unless a partnership or a financing arrives first.
The constructive case
The hypoimmune concept has human proof: a patient has carried allogeneic islet cells for more than a year without immunosuppression, with measurable beta cell function and no safety signal, and the result is published in a peer-reviewed journal. SC451 turns that into a scalable product from induced pluripotent stem cells, and SG293 turns the fusosome platform into an in vivo CAR T that could avoid the cost and logistics of ex vivo manufacturing. The company aims to share data from both programs in 2027.
The cautious case
One patient is not a trial. The UP421 result comes from an investigator-sponsored study with a single transplant, and the durability of immune evasion in a larger population, in the presence of an autoimmune disease that already destroyed the patient’s own islets, is unproven. The company has no revenue, a non-GAAP cash burn of $103.4 million in nine months, a runway that ends in mid-2027 and a share count that has grown 12.3% in nine months.
Latest Sana Biotechnology news
Nov 5, 2026
Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates
Cash, cash equivalents, and marketable securities were $121.7 million as of September 30, 2026, with cash runway expected into mid-2027. Research and development expenses were $33.9 million for the three months ended September 30, 2026, compared to $30.1 million in the same period of 2025. Sana expects to file an IND and begin a Phase 1/2 trial for SC451 as early as this year, and plans to start the SG293 clinical study in 1Q 2027.
Sep 8, 2026
Sana Biotechnology corporate presentation September 2026
The presentation states that about 10M people worldwide live with type 1 diabetes, almost 2M in the U.S. alone. Sana's 2026 goal is to file the SC451 IND and start a Phase 1/2 trial. For UP421, it reports HIP islet cell survival and function through 14 months with no therapy-related adverse events. It notes potential to share first-in-human data for SG293 in 1H 2027 and an expected start of a clinical study for SG227 as early as 2027.
Sep 8, 2026
updated clinical timetable
The corporate presentation retains a 2026 IND and trial-start goal for SC451 and places potential first human SG293 data in H1 2027. It reports completed GMP cell banks for SC451 while technology transfer and nonclinical work continue. These are development milestones and goals, not demonstrated SC451 patient benefit. Source
Aug 10, 2026
cash and the development bridge
Sana reports June cash and marketable securities of $160.490 million and expects funding into mid-2027. First-half operating cash use was $70.169 million. The later September presentation supersedes this release's earlier expectation of possible SG293 data during 2026. Source Source Source
Jul 13, 2026
UP421 follow-up reaches 14 months
The company announces a peer-reviewed follow-up reporting survival and function of modified donor islets in one person without immunosuppression. The low-dose study was not intended to establish insulin independence. The commercial-development candidate SC451 uses a separate stem cell-derived product. Source Source
Jul 1, 2026
EASD presentation announced
The UP421 symposium presentation was scheduled for October 2, 2026, from 09:10 to 09:30 CEST in Milan; the announced time has passed. The announcement establishes the event and subject; a conference slot alone does not establish the content or outcome of a new clinical disclosure. Source
SANA stock catalysts: the dated calendar
- 2025 — Internal manufacturing build-out suspended in the second quarter, with a $44.6 million non-cash impairment of long-lived assets; the two allogeneic CAR T programs suspended in November. Completed · company release · Form 10-Q
- August 2026 — Cobalt acquisition agreement amended, reducing estimated contingent consideration and producing a $55.5 million non-cash gain in the third quarter. Completed · company release
- 2026 — New England Journal of Medicine letter on 14-month survival of hypoimmune allogeneic islets without immunosuppression; data presented at the European Association for the Study of Diabetes annual meeting. Completed · company release
- November 5, 2026 — Third-quarter results: $121.7 million of cash and marketable securities, runway into mid-2027. Completed · company release
- As early as 2026 — Investigational new drug application and start of the SC451 Phase 1/2 trial in type 1 diabetes. Company guidance
- First quarter of 2027 — Start of the SG293 clinical study in non-Hodgkin lymphoma. Company guidance
- First half of 2027 — Potential first-in-human data for SG293. Company guidance
- 2027 — Data from SC451 and SG293, and potential clinical testing of SG227 in multiple myeloma. Company guidance
- Mid-2027 — End of the stated cash runway. Company guidance
The two platforms in one page
| Platform | What it does | Programs | Stage |
|---|---|---|---|
| Hypoimmune (HIP) | Deletes human leukocyte antigen (HLA) class I and II presentation and overexpresses CD47 so allogeneic cells evade T cells, natural killer cells and macrophages | UP421 (primary islets), SC451 (iPSC-derived islets) | UP421 in an investigator-sponsored first-in-human study; SC451 entering Phase 1/2 |
| Fusosome | Engineered delivery vehicle that targets a cell type and delivers genetic material in vivo | SG293 (CD19 CAR in CD8 T cells), SG227 (BCMA CAR in CD8 T cells) | SG293 clinical start guided to the first quarter of 2027; SG227 as early as 2027 |
The two platforms answer different questions. Hypoimmune editing asks whether a cell can be made invisible to the immune system, which would turn cell therapy into an off-the-shelf product. Fusosomes ask whether the body can be engineered in place, which would remove the manufacturing bottleneck. Both are ambitious, both have preclinical and, in one case, human support, and both are years from a commercial product. Science Translational Medicine, 2023
Sana Biotechnology deep dive: the full analysis
The chapters below work through the hypoimmune platform and the first human data, the SC451 program and the type 1 diabetes opportunity, the fusosome programs and the in vivo CAR T field, the third-quarter accounts, cash and burn, the share count and the 2026 financings, and the restructuring that narrowed the company in 2025. The same research is available as a downloadable PDF in the Research Library. The Merlintrader Research Library collects our dated biotech stock research reports.
01 Three scenarios: two platforms, one runway
Bull case — the hypoimmune concept holds in a trial and the fusosome works in patients
The favorable scenario is that SC451 reproduces in a Phase 1/2 what UP421 showed in one patient: islet cells that survive, produce insulin and escape rejection without immunosuppression, in a product that can be manufactured at scale from induced pluripotent stem cells. If that happens, Sana would own a platform for off-the-shelf cell therapy in type 1 diabetes, a disease with millions of patients and no cure, and the value of the company would be set by the platform rather than by a single program. Cell Stem Cell, 2024
The second half of the bull case is SG293. A CD8-targeted fusosome that generates CD19 CAR T cells inside a patient, without lymphodepleting chemotherapy and without a manufacturing plant, would address the cost and logistics that limit CAR T today. The first-in-human data are guided to the first half of 2027, and a signal of B cell depletion with manageable toxicity would validate the platform in a second, independent indication.
Base case — one program advances, the other slips, and a financing arrives
The base case is that SC451 starts on time and generates early safety and engraftment data in 2027, SG293 starts later than guided, and the company raises equity or signs a partnership before the runway ends in mid-2027, at a price set by whatever data exist. In that scenario the platforms remain credible, the timeline extends, and the equity is diluted but not broken.
That is the most likely path for a company with two platform bets and a runway that ends before either program can produce registrational data. The question for a reader is not whether the science is interesting, which it is, but how much of the value survives the financing that the runway requires.
Bear case — immune evasion does not scale, or the money runs out first
The negative scenario has two versions. In the first, the hypoimmune edit works in one patient but not in a population: the autoimmune response in type 1 diabetes is persistent and specific, and a cell that evades it in one transplant may not evade it in a larger trial, or the CD47 overexpression may create its own safety questions. In the second, the science is fine and the company runs out of money before the data arrive, because the runway into mid-2027 is shorter than the time needed for either program to read out.
Both versions end in the same place for the equity: a financing at a low price, a partnership that gives away most of the economics, or a strategic review. Sana has already narrowed its portfolio to concentrate resources, having suspended its two allogeneic CAR T programs in November 2025.
What would falsify this reading
The reading of this hub is that Sana is a platform company with one human proof of concept, two clinical starts in the next two quarters and a financing need that arrives before the data. Several observations would show that framing to be wrong.
The first would be a delay in the SC451 filing beyond the end of 2026. The company has guided to an investigational new drug application and a Phase 1/2 start as early as this year, and a slip would push everything that follows, including the financing conversation.
The second would be a safety event in the UP421 investigator-sponsored study. The 14-month data show no safety issues, and a signal in the longer follow-up, or in a second patient, would challenge the central claim of the platform rather than a single product.
The third would be evidence that the fusosome approach has already been overtaken. A CD8-targeted lipid nanoparticle has already reached patients with relapsed B cell lymphoma, as chapter 05 describes (Journal of Clinical Oncology (meeting abstract), 2026), and a larger or more durable result from that approach would narrow the competitive window further.
The fourth would be a financing that removes the option value: a large equity raise at a discount, or a partnership on SC451 that gives away the economics of the diabetes program in exchange for cash. Either would confirm the runway problem rather than the science.
02 What Sana does
Sana Biotechnology was founded in 2018 and is based in Seattle. It describes itself as a company creating and delivering engineered cells as medicines, and its work sits at the intersection of gene editing, cell therapy and delivery. Steve Harr is President and Chief Executive Officer. The company has no revenue and funds itself from the equity market.
The hypoimmune platform is the company’s signature. It starts from the observation that transplanted cells are rejected for two reasons: T cells recognize foreign HLA molecules, and natural killer cells and macrophages attack cells that lack them. The hypoimmune edit removes beta-2 microglobulin to eliminate HLA class I, removes the class II transactivator to eliminate HLA class II, and overexpresses CD47, the “don’t eat me” signal that macrophages recognize. The result, in preclinical work, is a cell that survives in an immunocompetent allogeneic host without immunosuppression. Nature Biotechnology, 2023
The fusosome platform is the delivery side. A fusosome is an engineered envelope that carries genetic material and targets a specific cell surface marker; Sana’s versions target CD8 to deliver a CAR construct to T cells in vivo. The appeal is that the patient’s own body becomes the manufacturing site, which removes the cost, the delay and the lymphodepletion that accompany ex vivo CAR T.
The company’s history includes a large initial public offering in 2021, a period of expansion into multiple programs, and a series of portfolio prioritizations: in 2025 it suspended the build-out of its internal manufacturing and took a $44.6 million impairment, and in November 2025 it suspended its two allogeneic CAR T programs. What remains is narrower and more focused: two platforms, one human proof of concept and two clinical starts.
03 UP421: the human proof of concept
UP421 is a primary human islet cell product edited with the hypoimmune modifications and transplanted into a patient with type 1 diabetes. The study is investigator-sponsored, conducted at Uppsala University Hospital under a clinical trial authorization, with Per-Ola Carlsson as principal investigator, and its purpose is to understand safety, immune evasion, islet survival and beta cell function in a patient who receives no immunosuppression.
The 14-month results, reported in 2026, are the most important data the company has. Circulating C-peptide was present, which indicates that the transplanted beta cells were producing insulin; C-peptide rose during mixed meal tolerance tests, consistent with a response to food, and fasting and stimulated levels at month 14 were comparable to those measured in the first six months; imaging at week 12 and week 52 showed islet cells at the transplant site in the forearm; and the company reports no safety issues and evidence that the cells evaded immune detection. Third-quarter release, November 5, 2026
The result was published as a letter in the New England Journal of Medicine and presented at the European Association for the Study of Diabetes annual meeting. Publication matters because it puts the claim in front of people who can check it, and because a letter in a major journal is a different kind of evidence from a company press release.
What the result does not show is equally important. It is one patient, in one investigator-sponsored study, with a follow-up measured in months rather than years. It does not show whether the cells produce enough insulin to free a patient from injections, that the effect persists, or that the immune evasion holds in a population whose autoimmune response has already destroyed their own islets. Those are the questions SC451 is designed to answer.
04 SC451 and type 1 diabetes
SC451 is the scalable version of UP421: an O-negative, hypoimmune-modified, induced pluripotent stem cell-derived pancreatic islet cell therapy, designed as a one-time treatment for type 1 diabetes with the goal of long-term normal blood glucose without insulin therapy or immunosuppression. The difference between the two products is the source of the cells. Primary islets come from donors and are scarce; induced pluripotent stem cells can be expanded and differentiated at scale, which is what makes an off-the-shelf product possible. Third-quarter release
The company expects to file an investigational new drug application and begin a Phase 1/2 trial as early as this year, and it has advanced a collaboration with Mayo Clinic to standardize the protocols and processes for delivering the product across clinical environments. Under the April 2026 license agreement with an affiliate of Mayo Clinic, Sana holds a non-exclusive license to certain know-how and intellectual property related to SC451 and islet cell therapy technologies and owes royalties on net sales of covered products (Form 10-Q). The company aims to share first data in 2027, and the company has said that SC451 may provide a rapid signal, similar to what was seen with UP421, on whether the therapy can evade immune detection and function in patients.
The clinical rationale is strong. Type 1 diabetes is an autoimmune disease in which the beta cells are destroyed, and the cell replacement available today, transplantation of donor islets, requires immunosuppression, which limits it to patients with the most severe disease. A product that needs no immunosuppression would open the therapy to a far larger population, and a product made from stem cells would remove the donor constraint.
The risks are equally clear. The autoimmune response that destroyed the patient’s own islets is still present, and a hypoimmune cell has to evade both the adaptive response against foreign HLA and the autoimmune response against beta cell antigens. The preclinical work suggests it can, in humanized mice and in non-human primates, but the human data so far come from a single transplant. Science Translational Medicine, 2023 · Cell Stem Cell, 2024 · Nature Biotechnology, 2023
05 SG293 and in vivo CAR T
SG293 is a CD8-targeted fusosome that delivers the genetic material to make CD19-directed CAR T cells. The design goal is to avoid the toxicities associated with in vivo CAR T, including reactions during infusion and delivery to tissues such as the liver, and to do so without lymphodepleting chemotherapy. Preclinical data presented at the American Society of Gene and Cell Therapy annual meeting in 2026 showed that a surrogate active in non-human primates achieved cell-specific delivery and deep B cell depletion, in circulating and lymph node B cells, with a phenotypic reset when B cells returned, and without lymphodepletion. Third-quarter release
The company plans to start a clinical study in the first quarter of 2027 and to share first-in-human data in non-Hodgkin lymphoma as early as the first half of 2027, with expansion into B cell-mediated autoimmune diseases if the results support it. Merlintrader reading: that timeline is aggressive for a first-in-human study, and it reflects the fact that the readout is a pharmacodynamic one: whether CAR T cells appear, whether B cells are depleted and whether the toxicity is manageable can be measured in weeks.
The competitive context has changed. A first-in-human study of a CD8-targeted lipid nanoparticle, presented in 2026 as a meeting abstract in a Journal of Clinical Oncology supplement, reported CAR T cell generation, near-complete peripheral B cell depletion within days, no cytokine release syndrome of grade 2 or higher, and early clinical activity in a small number of patients with relapsed B cell lymphoma. A 2025 paper in Science described targeted lipid nanoparticles that reprogrammed CD8 T cells in humanized mice and depleted B cells in cynomolgus monkeys. The concept is no longer only preclinical, and Sana’s fusosome has to show that its delivery vehicle is better, safer or more durable than the lipid nanoparticle approaches. Science, 2025
That is a different competitive position from the one the hypoimmune platform occupies, where the human data are Sana’s own. In in vivo CAR T the company is one of several, and the first-in-human data will be compared with results that already exist.
06 SG227 and the rest of the pipeline
SG227 is the second fusosome program: a CD8-targeted vehicle that delivers the genetic material to make B-cell maturation antigen (BCMA)-directed CAR T cells, for multiple myeloma. The BCMA CAR it delivers has been validated in the autologous setting and is approved in China, which reduces the biological risk of the payload; the risk sits in the delivery. Sana says it is preparing to begin clinical testing as early as 2027, contingent on the early clinical profile of SG293. Third-quarter release
The sequencing is deliberate. SG293 is the proof of the delivery platform in a disease where B cell depletion is an accepted endpoint; SG227 reuses the same delivery approach with a different payload in a disease where the target is validated but the competition is intense. If SG293 works, SG227 becomes a second indication for the same platform; if it does not, SG227 does not start.
Beyond those programs, the company’s earlier work in allogeneic CAR T has been suspended, and the pipeline is now concentrated on the two platforms. That concentration is a strength in a company with a short runway, because it stops the cash from being spread across programs that cannot all be funded, and a weakness because it leaves no fallback if the lead programs fail.
The business development angle is the fusogen technology, where payments Sana may receive from business development transactions help trigger the Cobalt contingent consideration, alongside development milestones. The estimated fair value of the success payment and contingent consideration liabilities moves with those assumptions, which is why the accounting result of this company is driven by estimates about programs that have not yet produced revenue (chapter 07 has the third-quarter effect).
07 Third-quarter 2026 results
Sana reported net income of $20.4 million, or $0.07 per share, for the third quarter under U.S. generally accepted accounting principles (GAAP), against a net loss of $42.2 million, or $0.16 per share, a year earlier. The swing is not operational: it comes from $63.4 million of non-cash gains on the change in fair value of success payment liabilities and contingent consideration, of which $55.5 million relates to the Cobalt contingent consideration after the August 2026 amendment to the acquisition agreement. The nine-month result was a net loss of $90.4 million, or $0.31 per share, against $185.3 million, or $0.75, in 2025. Third-quarter release, November 5, 2026
| $ millions | Q3 2026 | Q3 2025 | 9M 2026 | 9M 2025 |
|---|---|---|---|---|
| Research and development | 33.9 | 30.1 | 93.4 | 97.1 |
| General and administrative | 10.9 | 10.3 | 33.2 | 32.1 |
| Impairment of long-lived assets | — | — | — | 44.6 |
| Gain (expense) on success payments and contingent consideration | 63.4 | (3.1) | 31.0 | (15.3) |
| Net income (loss), GAAP | 20.4 | (42.2) | (90.4) | (185.3) |
| Non-GAAP net loss | (43.0) | (39.0) | (121.5) | (125.4) |
The non-GAAP net loss is the number that describes the operating business: $43.0 million in the quarter and $121.5 million in nine months, after excluding the non-cash fair value movements and the 2025 impairment. Research and development rose $3.8 million in the quarter on higher manufacturing costs at contract development and manufacturing organizations for SC451 and SG293 and higher laboratory costs for SC451, and fell $3.7 million over nine months, mainly on lower personnel-related, facility and allocated costs and because the suspended allogeneic CAR T programs no longer consume manufacturing and clinical budgets.
The expense base is now about $45 million a quarter, of which research and development is three quarters. That is a lean organization for a company running two platforms, and it reflects the portfolio prioritizations and workforce reductions of 2024 and 2025 described in the Form 10-Q.
08 Cash, burn and runway
Sana held $121.7 million of cash, cash equivalents and marketable securities at September 30, 2026, against $138.4 million at December 31, 2025. The $16.7 million decrease came from $108.9 million of cash used in operations and $2.7 million of property and equipment purchases, partly offset by $93.3 million of net proceeds from equity financings. The company guides to a runway into mid-2027. Third-quarter release
The arithmetic of the runway is the most important calculation in this hub. Non-GAAP operating cash burn was $103.4 million in the first nine months, about $11.5 million a month, and the company ended September with $121.7 million. At that rate (Merlintrader calculation) the cash lasts roughly ten and a half months from the end of September, which is around mid-August 2027, close to the company’s guidance. On the $108.9 million of cash used in operations under GAAP, the same arithmetic gives about ten months. The company derives the non-GAAP figure from the $16.7 million decrease in cash and securities by excluding $2.7 million of property and equipment purchases and a $3.8 million cash payment for a partial lease termination, and by removing $93.3 million of net equity proceeds (third-quarter release). Any acceleration in spending for the two clinical starts shortens the runway.
The quarterly report goes further than the runway guidance: management determined that current capital resources may not be sufficient to fund planned operations for at least one year from the date of the report, and that there is substantial doubt about the company’s ability to continue as a going concern. The company plans to address this through equity or debt offerings or capital from strategic collaborations or licensing. Form 10-Q, September 30, 2026
The company has been funding itself through the equity market. Net proceeds of $93.3 million in the first nine months of 2026 came from financings that also increased the share count from 266.7 million to 299.5 million. They include the sale of 7.5 million shares to Mayo Clinic at $3.33 per share in April 2026, about $25.0 million gross, and sales under the at-the-market facility of up to $150.0 million: in a Form 8-K filed on May 15, 2026 the company reported 21,607,878 shares sold under the facility for net proceeds of approximately $69.0 million (Form 8-K), and none were sold in the third quarter (Form 10-Q). Mayo Clinic did not elect to buy an additional 7.5 million shares at $3.33 per share before its option expired on August 31, 2026. Merlintrader reading: the pattern is likely to repeat before the runway ends. The alternative is a partnership on SC451 or on the fusosome platform, which would bring money at the cost of economics.
For a reader, the runway is not a detail; it is the constraint that determines which programs get funded and on what terms. A company with $121.7 million and two clinical starts has enough money to reach the first data, not enough to reach a registration, and the financing that closes the gap will be priced on those first data.
09 Shares and the 2026 financings
Sana had 299,521 thousand shares of common stock issued and outstanding at September 30, 2026, against 266,732 thousand at December 31, 2025, an increase of 12.3%, and the cover of the quarterly report shows 299,634,951 shares outstanding at October 29, 2026. The company has 750,000 thousand shares authorized and 50,000 thousand shares of preferred stock authorized with none outstanding. The increase reflects the equity financings that produced $93.3 million of net proceeds in the first nine months. Options to purchase 28.1 million shares were outstanding at September 30, 2026, with a weighted-average exercise price of $5.45. Form 10-Q, September 30, 2026
Recent Schedule 13G filings report four holders above 5%: funds affiliated with ARCH Venture Partners reported 45,860,681 shares, 15.3% of the class, at June 30, 2026 (amendment filed August 14, 2026); FMR LLC (Fidelity) reported 37,293,854 shares, 12.5%, at September 30, 2026 (amendment filed November 5, 2026); RA Capital Management reported 18,750,000 shares, 6.3%, at May 14, 2026 (filed May 21, 2026); and BlackRock reported 13,643,304 shares, 5.1%, at December 31, 2025 (filed January 21, 2026). Each percentage is as reported by the filer at its own reference date. The Form 4 filings of 2026 report award grants, vesting of restricted stock units and shares withheld for taxes (transaction codes A, M and F); none reports an open-market purchase or sale (codes P or S) by a director or officer.
The dilution is the price of the runway. A company that burns more than $100 million a year with no revenue has to sell equity, and the terms depend on the data available at the time. Sana raised in 2026 before the SC451 and SG293 data; Merlintrader reading: the shares were sold on the strength of the UP421 result and the platform narrative rather than on clinical evidence from its own lead programs.
The share count also matters for the contingent consideration. Under the Cobalt acquisition agreement, as amended in August 2026, Sana owes up to $500.0 million of contingent consideration and up to a $500.0 million success payment, each payable in cash or stock; nothing had been triggered at September 30, 2026 (Form 10-Q). The fair value of these liabilities depends on development milestones, on payments Sana may receive from business development transactions involving the fusogen technology, and on the company’s market capitalization and share price. A higher share price increases the liability and produces an expense; a lower one produces a gain. In the third quarter, however, most of the $63.4 million gain, $55.5 million, came from the Cobalt contingent consideration, primarily because of the August 2026 amendment rather than the share price. These are non-cash movements, and they are the reason the GAAP net income of $20.4 million in the third quarter should not be read as profitability.
Sana has never declared or paid a cash dividend and does not intend to (Form 10-Q). The only route to a return is the success of the programs or a strategic transaction.
10 The 2025 restructuring
In the second quarter of 2025 Sana suspended the build-out of its internal manufacturing, concluding that contract development and manufacturing organizations could meet its near-term needs. The decision produced a non-cash impairment of long-lived assets of $44.6 million, primarily related to the manufacturing facility in Bothell, Washington and to laboratory and office space in Seattle. Third-quarter release In November 2025 the company conducted a portfolio prioritization to prioritize SC451 and its fusogen programs and suspended development of its two allogeneic CAR T programs, SC291 in B-cell mediated autoimmune diseases and SC262 in oncology, winding down their Phase 1 trials (Form 10-Q).
The restructuring explains the shape of the company today. Research and development expense fell over nine months mainly on lower personnel-related, facility and allocated costs and because the suspended programs no longer consume manufacturing and clinical budgets, and the organization is smaller than it was at the time of the initial public offering. The stated logic was to prioritize resources on SC451 and the fusogen programs, where the company saw promising data.
The cost of that decision is visible in the pipeline: the company no longer has a clinical-stage allogeneic CAR T program, and its value now depends on two earlier-stage platforms. The benefit is that the cash lasts longer and the story is simpler, which matters for a company that keeps returning to the equity market.
For a reader, the restructuring is evidence about management’s willingness to cut. That is a positive in a sector where companies often keep programs alive past the point of funding them, and a caution because it shows how quickly a platform company can be forced to choose.
11 Red flags and assessment
The first red flag is the evidence base. The hypoimmune platform’s human proof is one patient in an investigator-sponsored study, published as a letter, with 14 months of follow-up. It is a genuine result and it is not a trial.
The second is the runway. $121.7 million at September 30, 2026, a non-GAAP burn of about $11.5 million a month, a stated runway into mid-2027 and the going-concern doubt in the Form 10-Q mean the company will need to raise money before either lead program produces data that could support a valuation.
The third is the competitive position in in vivo CAR T. A first-in-human study of a CD8-targeted lipid nanoparticle reported CAR T generation and B cell depletion in patients in 2026, which means Sana’s fusosome is not the first approach to reach patients and will be compared with data that already exist.
The fourth is the accounting. The GAAP net income of $20.4 million in the third quarter came from non-cash fair value gains on contingent consideration, and the non-GAAP net loss was $43.0 million. A reader who takes the headline number at face value would misread the company’s financial position.
The fifth is the concentration. Two platforms, two clinical starts and no fallback: if SC451 fails on immune evasion, the hypoimmune thesis weakens; if SG293 fails on delivery, the fusosome thesis weakens. The company has already narrowed its portfolio once to concentrate resources, and there is not much left to cut.
The sixth is litigation. A putative securities class action filed in March 2025 in the U.S. District Court for the Western District of Washington (case 2:25-cv-00512) names the company and current and former executives and alleges false and misleading statements about the development of SC291, the allogeneic CAR T candidate Sana has since suspended, and about the company’s finances and prospects, on behalf of purchasers between January 9 and November 4, 2024. The complaint seeks unspecified damages. The defendants moved on September 8, 2026 to dismiss the second amended complaint, and the Form 10-Q states that they intend to defend themselves vigorously and that there can be no assurance as to the outcome. Form 10-Q, Part II, Item 1
Sana in late 2026 is a platform company with a striking human proof of concept, a credible second platform, two clinical starts in the next two quarters and a balance sheet that runs out before the data mature. The equity is a claim on whether the hypoimmune concept scales and on the price at which the next financing arrives.
Merlintrader Health Score · $SANA
2.65out of 5
Assessed on November 19, 2026, on the quarter ended September 30, 2026. Weighted calculation: 1.5×30% + 4.0×30% + 2.0×20% + 3.0×10% + 3.0×10% = 0.45 + 1.20 + 0.40 + 0.30 + 0.30 = 2.65. The score describes financial and operational robustness over twelve to eighteen months. It is not a rating, a target price or an indication to buy or sell.
Red flags
- The hypoimmune human evidence is one patient in an investigator-sponsored study, not a controlled trial.
- $121.7 million of cash at September 30, 2026 and a runway into mid-2027, before either lead program reads out.
- The Form 10-Q for the quarter ended September 30, 2026 states substantial doubt about the company’s ability to continue as a going concern.
- No revenue, and a non-GAAP net loss of $121.5 million in the first nine months.
- The GAAP net income of $20.4 million in the third quarter came from non-cash fair value gains, not operations.
- Shares rose 12.3% in nine months, to 299.5 million, and another financing is likely.
- In vivo CAR T has already reached patients through a competing CD8-targeted lipid nanoparticle approach.
- The allogeneic CAR T programs were suspended in November 2025, after a $44.6 million impairment on internal manufacturing earlier that year, leaving two platform bets and no fallback.
- A putative securities class action over statements made in 2024 is pending against the company and current and former executives.
- Contingent consideration and success payment liabilities move with the share price and with development milestones, so the accounting result is volatile.
SANA Stock FAQ: Sana Biotechnology Questions Answered
When is the next SANA stock catalyst?
Sana guides to filing an investigational new drug application and starting a Phase 1/2 trial for SC451 in type 1 diabetes as early as 2026, and to starting a clinical study of SG293 in the first quarter of 2027, with first-in-human data in non-Hodgkin lymphoma as early as the first half of 2027. Details.
Has the Food and Drug Administration (FDA) approved any Sana product?
No. Sana has no approved product and no product revenue. Its lead programs are in or entering first-in-human testing: UP421 in an investigator-sponsored study in type 1 diabetes, SC451 entering Phase 1/2, and SG293 entering a clinical study in non-Hodgkin lymphoma. Details.
How much revenue does Sana make?
None. Sana is pre-commercial and has generated no revenue from product sales or any other source since inception; its income statement is driven by research and development expense and by non-cash fair value movements on contingent consideration and success payment liabilities. Details.
How much cash does Sana have, and how long will it last?
Sana reported $121.7 million of cash, cash equivalents and marketable securities at September 30, 2026, against $138.4 million at December 31, 2025, and guides to a runway into mid-2027. Non-GAAP operating cash burn was $103.4 million in the first nine months of 2026, and the Form 10-Q states substantial doubt about the company’s ability to continue as a going concern. Details.
Is SANA stock at risk of dilution?
Yes. Sana had 299,521 thousand shares outstanding at September 30, 2026, up from 266,732 thousand at December 31, 2025, after $93.3 million of net equity proceeds, and it will need to raise again before the runway ends in mid-2027 unless a partnership brings cash in. Details.
When does Sana report earnings?
Sana reported third-quarter 2026 results on November 5, 2026, with GAAP net income of $20.4 million, a non-GAAP net loss of $43.0 million and $121.7 million of cash and marketable securities. The company reported fourth-quarter and full-year 2025 results on March 3, 2026; as of November 19, 2026 it had not announced a date for its fourth-quarter and full-year 2026 report. Details.
What does Sana Biotechnology do?
Sana is a Seattle-based biotechnology company developing engineered cell therapies on two platforms: hypoimmune editing, which modifies donor cells so they evade rejection without immunosuppression, and fusosomes, which deliver genetic material to selected cells in the body. Its lead programs are SC451 in type 1 diabetes and SG293 in B cell lymphoma. Details.
What did the UP421 study show?
UP421, a hypoimmune-modified primary islet cell therapy, was transplanted into a patient with type 1 diabetes without immunosuppression. At 14 months the patient had circulating C-peptide and no safety issues, and the result was published as a letter in the New England Journal of Medicine; chapter 03 has the full results. Details.
Primary sources
- Third-quarter 2026 results and business updates, November 5, 2026 (Form 8-K, Exhibit 99.1)
- Quarterly report on Form 10-Q for the quarter ended September 30, 2026, filed November 5, 2026
- Current report on Form 8-K, May 15, 2026 (at-the-market sales)
- Current report on Form 8-K dated April 10, 2026 (Mayo Clinic stock purchase agreement)
- “Long-term survival of hypoimmune allogeneic islets without immunosuppression”, New England Journal of Medicine, 2026
- Hu X. et al., “Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice”, Science Translational Medicine, 2023
- Hu X. et al., “Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate”, Cell Stem Cell, 2024
- Hu X. et al., “Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques”, Nature Biotechnology, 2023
- Hunter T. et al., “In vivo CAR T cell generation to treat cancer and autoimmune disease”, Science, 2025
- Zhang X. et al., “First-in-human in vivo CAR T-cell generation using a CD8-targeted lipid nanoparticle platform in relapsed/refractory B-cell lymphoma”, Journal of Clinical Oncology (meeting abstract), 2026
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $SANA or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and peer-reviewed publications, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.
Clinical-stage biotechnology companies carry scientific, regulatory, manufacturing and financing risk. A first-in-human result in one patient can fail to replicate in a trial, an immune-evasion strategy can be overcome by an autoimmune response, a delivery platform can prove less specific in humans than in animals, and companies without revenue must raise equity on whatever terms the market offers. This company reported $121.7 million of cash at September 30, 2026, a runway into mid-2027, no revenue and a non-GAAP net loss of $121.5 million in the first nine months. Every reader is responsible for their own decisions and should consult a licensed financial advisor where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



